within Pharmacolibrary.Drugs.ATC.R;

model R03BB07
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0025166666666666666,
    adminDuration  = 600,
    adminMass      = 125 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.086,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 1.96,
    k12             = 358,
    k21             = 358
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03BB07</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Umeclidinium bromide is a long-acting muscarinic antagonist (LAMA) used as a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is administered as an inhalation powder and is approved for use in adults to improve airflow and reduce symptoms in COPD patients.</p><h4>Pharmacokinetics</h4><p>Reported PK parameters in healthy adult subjects following inhaled administration of umeclidinium bromide.</p><h4>References</h4><ol><li><p>Kelleher, DL, et al., &amp; Thomas, P (2012). Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. <i>PloS one</i> 7(12) e50716–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0050716&quot;>10.1371/journal.pone.0050716</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23284643/&quot;>https://pubmed.ncbi.nlm.nih.gov/23284643</a></p></li><li><p>Mehta, R, et al., &amp; Lipson, DA (2020). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. <i>Clinical pharmacokinetics</i> 59(1) 67–79. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00794-w&quot;>10.1007/s40262-019-00794-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31321713/&quot;>https://pubmed.ncbi.nlm.nih.gov/31321713</a></p></li><li><p>Segreti, A, et al., &amp; Cazzola, M (2014). Umeclidinium for the treatment of chronic obstructive pulmonary disease. <i>Expert review of respiratory medicine</i> 8(6) 665–671. DOI:<a href=&quot;https://doi.org/10.1586/17476348.2014.962519&quot;>10.1586/17476348.2014.962519</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25312239/&quot;>https://pubmed.ncbi.nlm.nih.gov/25312239</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03BB07;
